Media

BIOSPACE
BIOSPACE

Foghorn and Merck Ink Strategic Collaboration in Cancer for $425 Million+

July 8, 2020

XCONOMY
XCONOMY

Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck

July 8, 2020

FIERCE BIOTECH
FIERCE BIOTECH

Merck teams up with cancer startup Foghorn in $425M deal

July 8, 2020

BIOTECH 2050
BIOTECH 2050

Podcast Ep. 9 – Carl P. Decicco, PhD, Chief Scientific Officer, Foghorn Therapeutics

January 23, 2020

WUXI APPTEC
WUXI APPTEC

Innovation that Matters: Foghorn® Therapeutics’ Gene Traffic Control Product™ Platform

October 30, 2019

XCONOMY
XCONOMY

Foghorn Therapeutics Adds Samuel Agresta, Allan Reine to C-Suite

September 19, 2019

FIERCEBIOTECH
FIERCEBIOTECH

Foghorn and Rgenix nab Agios, Roche veterans as new CMOs

September 16, 2019

PHARMAVOICE
PHARMAVOICE

CEO Adrian Gottschalk Named to PharmaVOICE 100

August 1, 2019

VENTURE CAPITAL HORIZONS REVISITING HEALTHCARE
VENTURE CAPITAL HORIZONS REVISITING HEALTHCARE

Foghorn Therapeutics: A pioneer in chromatin biology

June 11, 2019

C&EN NEWS
C&EN NEWS

Foghorn Therapeutics takes aim at chromatin hijackers to stop cancer

May 12, 2019